GAMMA Investing’s Adicet Bio ACET Stock Holding History

GAMMA Investing’s Portfolio ACET Stock Details ACET Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-239	Closed	-$4.63K	–	3576
2024 Q2	$4.63K	Hold	239	–	–	﹤0.01%	2608
2024 Q1	$9K	Hold	239	–	–	﹤0.01%	2121
2023 Q4	$11.4K	Buy	+239	New	+$5.21K	﹤0.01%	1834

Other funds holding ACET

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

GAMMA Investing's ACET Position: Q3 2024 in Review

GAMMA Investing sold out of Adicet Bio (ACET) in Q3 2024, closing a stake of 239 shares — an estimated $4.63K sold.

GAMMA Investing first reported a position in ACET in Q4 2023 and held it in 3 quarters. The position peaked at $11.4K in Q4 2023. 64 funds tracked by Wall St. Rank hold ACET as of Q3 2024.

GAMMA Investing reported no remaining Adicet Bio position as of Q3 2024 after selling out during the quarter.
GAMMA Investing sold 239 Adicet Bio shares in Q3 2024, an estimated $4.63K.
GAMMA Investing first reported a position in Adicet Bio in Q4 2023 and held it in 3 quarters.
GAMMA Investing's Adicet Bio position peaked at $11.4K in Q4 2023.
64 funds tracked by Wall St. Rank held Adicet Bio as of Q3 2024.

Based on GAMMA Investing's 13F filing for Q3 2024, filed 7 Oct 2024.